尿嘧啶/替加氟作为化疗难治性结直肠癌患者可能的挽救治疗：一项单机构回顾性研究

Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study.

作者信息

Bayoglu İbrahim V, Yildiz Ibrahim, Varol Umut, Cokmert Suna, Alacacıoğlu Ahmet, Kucukzeybek Yuksel, Akyol Murat, Demir Lutfiye, Dirican Ahmet, Tarhan Oktay

机构信息

Department of Medical Oncology, Izmir Katip Celebi University Ataturk, Training and Research Hospital, Turkey.

出版信息

Contemp Oncol (Pozn). 2015;19(5):385-90. doi: 10.5114/wo.2015.53374. Epub 2015 Aug 13.

DOI:10.5114/wo.2015.53374

PMID:26793023

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4709396/

Abstract

AIM OF THE STUDY

Our aim was to determine the activity and toxicity of uracil/tegafur and leucovorin combination in metastatic colorectal cancer (mCRC) patients who have progressed with all currently active agents.

MATERIAL AND METHODS

This study was a retrospective analysis of 50 mCRC patients who had previously failed to respond to all available chemotherapeutics and who received subsequent treatment with uracil/tegafur 250 mg/m(2) d1-5 in combination with leucovorin 90 mg/day, d1-5 followed by two days' rest.

RESULTS

The median age of the patients was 60 years. Most of them (60%) were male. Bevacizumab was used in 65% and cetuximab in 55% of the patients. Thirty-nine patients (78%) were treated with uracil/tegafur in the fourth line setting. The median treatment duration was 4.2 months (range, 2-24 months). The objective response rate and the disease control rate were 4% and 34%, respectively. Median progression-free survival was 4.1 months (95% CI, 3.6-4.6 months) and overall survival was 6.6 months (95% CI, 4.5-8.6 months). Grade 3 or 4 toxicity was seen in 20% (n = 10) of the patients while 60% (n = 6) of them required dose reductions.

CONCLUSIONS

This retrospective data show that uracil/tegafur may be considered in heavily pretreated mCRC patients because of its activity, lower toxicity, and feasibility.

摘要

研究目的

我们的目的是确定在所有当前有效药物治疗均进展的转移性结直肠癌（mCRC）患者中，尿嘧啶/替加氟与亚叶酸联合用药的活性和毒性。

材料与方法

本研究是对50例mCRC患者的回顾性分析，这些患者先前对所有可用化疗药物均无反应，并随后接受尿嘧啶/替加氟250mg/m²，第1 - 5天，联合亚叶酸90mg/天，第1 - 5天，随后休息两天的治疗。

结果

患者的中位年龄为60岁。其中大多数（60%）为男性。65%的患者使用了贝伐单抗，55%的患者使用了西妥昔单抗。39例（78%）患者在四线治疗时接受了尿嘧啶/替加氟治疗。中位治疗持续时间为4.2个月（范围2 - 24个月）。客观缓解率和疾病控制率分别为4%和34%。中位无进展生存期为4.1个月（95%CI，3.6 - 4.6个月），总生存期为6.6个月（95%CI，4.5 - 8.6个月）。20%（n = 10）的患者出现3级或4级毒性，其中60%（n = 6）的患者需要降低剂量。